HUE050320T2 - PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onok - Google Patents
PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onokInfo
- Publication number
- HUE050320T2 HUE050320T2 HUE17715943A HUE17715943A HUE050320T2 HU E050320 T2 HUE050320 T2 HU E050320T2 HU E17715943 A HUE17715943 A HU E17715943A HU E17715943 A HUE17715943 A HU E17715943A HU E050320 T2 HUE050320 T2 HU E050320T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrazolo
- dihydro
- ones
- pyrimidin
- pyridin
- Prior art date
Links
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 title 1
- MPOYBFYHRQBZPM-UHFFFAOYSA-N 3h-pyridin-4-one Chemical class O=C1CC=NC=C1 MPOYBFYHRQBZPM-UHFFFAOYSA-N 0.000 title 1
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600221 | 2016-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050320T2 true HUE050320T2 (hu) | 2020-11-30 |
Family
ID=58489694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17715943A HUE050320T2 (hu) | 2016-04-12 | 2017-04-07 | PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onok |
Country Status (43)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| HUE050403T2 (hu) | 2016-10-28 | 2020-12-28 | H Lundbeck As | Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére |
| BR112018013084A2 (pt) | 2016-10-28 | 2018-12-11 | H Lundbeck As | tratamentos de combinação compreendendo a administração de imidazopirazinonas |
| AU2017388054B2 (en) | 2016-12-28 | 2022-03-24 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
| CA3120971A1 (en) * | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| CN112189013A (zh) | 2018-05-25 | 2021-01-05 | 细胞内治疗公司 | 有机化合物 |
| CN115304607B (zh) * | 2022-07-06 | 2023-06-27 | 华南农业大学 | 吡唑并嘧啶衍生物的制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) * | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| DE10238724A1 (de) * | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| EP1626971B1 (de) * | 2003-05-09 | 2011-08-10 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| DK2152712T3 (da) * | 2007-05-11 | 2012-03-26 | Pfizer | Aminoheterocykliske fobindelser |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
| KR20110098731A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| JP5879336B2 (ja) * | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| WO2012040230A1 (en) | 2010-09-20 | 2012-03-29 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN104703987B (zh) | 2011-10-10 | 2017-05-03 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| SG11201403909RA (en) | 2012-01-26 | 2014-10-30 | Lundbeck & Co As H | Pde9 inhibitors with imidazo triazinone backbone |
| CA2877149C (en) | 2012-06-18 | 2021-01-19 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine azolopyrimidine-5-(6h)-one compounds |
| ES2836129T3 (es) | 2013-03-15 | 2021-06-24 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| TW201609713A (zh) * | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20170273985A1 (en) | 2014-09-18 | 2017-09-28 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| BR112018013084A2 (pt) | 2016-10-28 | 2018-12-11 | H Lundbeck As | tratamentos de combinação compreendendo a administração de imidazopirazinonas |
| HUE050403T2 (hu) | 2016-10-28 | 2020-12-28 | H Lundbeck As | Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére |
-
2017
- 2017-04-05 TW TW106111366A patent/TWI729109B/zh not_active IP Right Cessation
- 2017-04-06 US US15/481,083 patent/US20170291901A1/en not_active Abandoned
- 2017-04-07 KR KR1020187029341A patent/KR20180133413A/ko not_active Ceased
- 2017-04-07 HR HRP20201331TT patent/HRP20201331T1/hr unknown
- 2017-04-07 RS RS20200994A patent/RS60714B1/sr unknown
- 2017-04-07 ME MEP-2020-169A patent/ME03820B/me unknown
- 2017-04-07 MY MYPI2018001605A patent/MY194722A/en unknown
- 2017-04-07 SG SG11201808221QA patent/SG11201808221QA/en unknown
- 2017-04-07 EA EA201891897A patent/EA035197B1/ru not_active IP Right Cessation
- 2017-04-07 SM SM20200446T patent/SMT202000446T1/it unknown
- 2017-04-07 PT PT177159431T patent/PT3442975T/pt unknown
- 2017-04-07 CR CR20180470A patent/CR20180470A/es unknown
- 2017-04-07 CA CA3020053A patent/CA3020053A1/en not_active Abandoned
- 2017-04-07 WO PCT/EP2017/058332 patent/WO2017178350A1/en not_active Ceased
- 2017-04-07 LT LTEP17715943.1T patent/LT3442975T/lt unknown
- 2017-04-07 CN CN201780022870.0A patent/CN109071549B/zh active Active
- 2017-04-07 PE PE2018001912A patent/PE20181853A1/es unknown
- 2017-04-07 AU AU2017250431A patent/AU2017250431B2/en not_active Ceased
- 2017-04-07 JP JP2018550733A patent/JP7093306B2/ja active Active
- 2017-04-07 SI SI201730387T patent/SI3442975T1/sl unknown
- 2017-04-07 MX MX2018012496A patent/MX374251B/es active IP Right Grant
- 2017-04-07 PL PL17715943T patent/PL3442975T3/pl unknown
- 2017-04-07 GE GEAP201714901A patent/GEP20207057B/en unknown
- 2017-04-07 MA MA44656A patent/MA44656B1/fr unknown
- 2017-04-07 RU RU2018133391A patent/RU2018133391A/ru unknown
- 2017-04-07 TN TNP/2018/000321A patent/TN2018000321A1/en unknown
- 2017-04-07 ES ES17715943T patent/ES2814289T3/es active Active
- 2017-04-07 EP EP17715943.1A patent/EP3442975B1/en active Active
- 2017-04-07 DK DK17715943.1T patent/DK3442975T3/da active
- 2017-04-07 UA UAA201809742A patent/UA121925C2/uk unknown
- 2017-04-07 HU HUE17715943A patent/HUE050320T2/hu unknown
- 2017-04-07 BR BR112017026278-9A patent/BR112017026278A2/pt not_active Application Discontinuation
- 2017-04-10 AR ARP170100915A patent/AR108109A1/es unknown
-
2018
- 2018-08-01 US US16/051,612 patent/US10538525B2/en active Active
- 2018-09-19 DO DO2018000201A patent/DOP2018000201A/es unknown
- 2018-09-25 NI NI201800092A patent/NI201800092A/es unknown
- 2018-09-26 ZA ZA2018/06407A patent/ZA201806407B/en unknown
- 2018-09-26 CO CONC2018/0010323A patent/CO2018010323A2/es unknown
- 2018-09-28 SV SV2018005753A patent/SV2018005753A/es unknown
- 2018-10-03 EC ECSENADI201874641A patent/ECSP18074641A/es unknown
- 2018-10-09 PH PH12018502168A patent/PH12018502168A1/en unknown
- 2018-10-10 IL IL262257A patent/IL262257B/en active IP Right Grant
- 2018-10-10 CL CL2018002881A patent/CL2018002881A1/es unknown
-
2019
- 2019-12-03 US US16/701,269 patent/US11104680B2/en not_active Expired - Fee Related
-
2020
- 2020-08-20 CY CY20201100779T patent/CY1123269T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE050320T2 (hu) | PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onok | |
| FR22C1058I1 (fr) | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide | |
| DK3470519T3 (da) | Hidtil ukendte crispr-enzymer og -systemer | |
| IL255801A (en) | Liposomal nanoconstructs and methods of making and using the same | |
| HUE043122T2 (hu) | Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk | |
| HUE055233T2 (hu) | Az EGFR gátló és annak elkészítése és alkalmazása | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| SG11201704897QA (en) | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | |
| HUE061576T2 (hu) | Kevert allergén készítmények és eljárások alkalmazásukra | |
| DK3288942T3 (da) | Rsv-antivirale pyrazolo- og triazolopyrimidinforbindelser | |
| SG10202003053VA (en) | Deactivation wipe kit and method of forming and using the same | |
| HUE048576T2 (hu) | 1H-pirazolo[4,3B]piridinek, mint PDE1 inhibitorok | |
| EP3722298A4 (en) | PYRROLO DERIVATIVE (PYRAZOLO) PYRIMIDINE USED AS LRRK2 INHIBITOR | |
| PL3262987T3 (pl) | Regał dozujący jak też zestaw do jego wytwarzania | |
| EP3498707A4 (en) | FGFR4 INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | |
| IL261835A (en) | Analytical methods and arrays for their use | |
| IL261438A (en) | Polymalic acid based nanoimmunoconjugates and uses thereof | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| ZA201902325B (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| EP3334730A4 (en) | Pyrrolomycins and methods of using the same | |
| ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| IT201700028709A1 (it) | Acidi-5-carbossamide-2-tiobarbiturici e loro uso come medicamenti | |
| HK40097160A (zh) | 抗tim-3抗体及其用途 | |
| HK40018954A (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| AU2016904076A0 (en) | Search and rescue beacon |